Remdesivir has been shown to be effective against COVID-19. Clinical data indicates Remdesivir is safer than alternative Favipiravir and also more effective. Van Buren said data gathered from 200 patients is “highly encouraging” and Remdesivir drug trials are positive.
Trials conducted in China and Japan indicate that Favipiravir, which is manufactured by Toyama Chemical Co. owned by FUJIFILM Holdings Corp (OTC:FUJIY) under the brand name Avigan, also has efficacy against RNA viruses. The drug is somewhat effective in treating COVID-19, but needs to be used early on, according to Japanese officials.
Van Buren said there are currently five Remdesivir trials underway, of which two are in China. China’s test results should be out by the end of the month. Gilead’s own two trial results will follow next. These are shorter 14-day trials but with restrictive entry criteria. A 30-day NIAID Hospitalized US Adult Phase II trial is also being carried out to measure Remdesivir’s efficacy against a placebo.
Remdesivir is likely to be approved for broad use in the coming months, Van Buren wrote in a note. Due to the COVID-19 epidemic, the U.S. Food and Drug Administration may consider fast-tracking approval.
The Gilead Thesis
Remdesivir has been shown to be effective against COVID-19. Clinical data indicates Remdesivir is safer than alternative Favipiravir and also more effective. Van Buren said data gathered from 200 patients is “highly encouraging” and Remdesivir drug trials are positive.
Trials conducted in China and Japan indicate that Favipiravir, which is manufactured by Toyama Chemical Co. owned by FUJIFILM Holdings Corp (OTC:FUJIY) under the brand name Avigan, also has efficacy against RNA viruses. The drug is somewhat effective in treating COVID-19, but needs to be used early on, according to Japanese officials.
Van Buren said there are currently five Remdesivir trials underway, of which two are in China. China’s test results should be out by the end of the month. Gilead’s own two trial results will follow next. These are shorter 14-day trials but with restrictive entry criteria. A 30-day NIAID Hospitalized US Adult Phase II trial is also being carried out to measure Remdesivir’s efficacy against a placebo.
Remdesivir is likely to be approved for broad use in the coming months, Van Buren wrote in a note. Due to the COVID-19 epidemic, the U.S. Food and Drug Administration may consider fast-tracking approval.
同学，这个真是急不得。等临床试验结果。
这病长远看只能靠药靠疫苗，现阶段的隔离只能暂时搞搞，再这么搞下去，全世界经济都要崩溃了，大家不病死也要饿死。
新冠不是埃博拉不是烈性鼠疫，这后两种病死亡率高，传染性没那么大，局部隔离封杀一下，确实可以压制下去。
但新冠是更接近流感的特性，杀不死灭不绝，只有出现有效药和疫苗才能让人放心。
发到新英格兰，基本没有提这个药，主要讲了抗艾滋药
美国自己在做，4 月可以接盲